Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Del-desiran (AOC 1001)
Del-desiran · 1 trial · 8 indications
Incidence of treatment emergent adverse events
| Arm | Type | Description |
|---|---|---|
| Del-desiran | EXPERIMENTAL | Del-desiran (AOC 1001) will be administered seven times per year for up to 4 years. |
| Name | Type | Description |
|---|---|---|
| Del-desiran (AOC 1001) | DRUG | Del-desiran will be administered by intravenous (IV) infusion. |
FROM A PARENT STUDY Key Inclusion Criteria: * Completion of any prior AOC 1001 studies with satisfactory completion of dosing and follow-up assessments and satisfactory compliance with the protocol requirements of the parent study, as determined by the Investigator. Key Exclusion Criteria: * Bre...
Del-desiran is an investigational small molecule being developed for the treatment of Myotonic Dystrophy Type 1 (DM1), a rare genetic disorder. It is currently in Phase 3 clinical development and is being studied in an open-label extension trial for patients with DM1.
Del-desiran is being developed by Atrium Therapeutics, Inc., a biopharmaceutical company. The company is conducting a Phase 3 clinical trial of Del-desiran for the treatment of Myotonic Dystrophy Type 1.
Del-desiran is currently in Phase 3 clinical development. It is being evaluated in an open-label extension study for the treatment of Myotonic Dystrophy Type 1. The drug is investigational and has not been approved by regulatory authorities.
Del-desiran is being studied in a Phase 3 open-label extension trial with the identifier NCT07008469. This trial is enrolling patients with Myotonic Dystrophy Type 1 by invitation and aims to enroll approximately 199 participants across multiple countries.
Yes, Del-desiran is also known as AOC 1001. It is an investigational small molecule being developed by Atrium Therapeutics, Inc. for the treatment of Myotonic Dystrophy Type 1.
Del-desiran is a small molecule with a target class of -siran, which indicates it is a small interfering RNA (siRNA) therapeutic. It is designed to target the underlying cause of Myotonic Dystrophy Type 1, though the specific molecular target is not disclosed.